Tuesday 13 May 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Pharmaceutical Trends In South Africa; What Future?

Pharmaceutical Trends In South Africa; What Future?

16 October 1994

The first democratic election in 300 years in South Africa introduced the world's newest democracy, but there is still great uncertainty about the overall economic philosophy to be followed in South Africa. Although there is a fair amount of talk about retaining the free market system, it seems that it may not be the case in respect of certain industries - one of which could be the pharmaceutical manufacturing industry.

The African National Congress released a National Health Plan based on the primary health care approach in April this year, immediately after the elections. This is regarded by many as setting goals rather than a practical plan to introduce a new health care system. In fact, the document acknowledges the need for appropriate data and recommends further research. However, as apartheid created a fragmented system with "inequitable access and a bias towards curative care and the private sector," the ANC's insistence on "a complete transformation of the health care delivery system and all relevant institutions" in order to redress social and economic injustices, is not negotiable.

While only stating that a "single, comprehensive, equitable and integrated national health system" should be created, it seems clear that the prime objective of the ANC is to introduce a National Health Scheme, possibly based on principles applied in the UK. Some ANC representatives hold the view that the private sector will continue only in the interim, until the NHS has been put into place. If an NHS is the objective, it could have a major impact on private health care services, as well as on the pharmaceutical industry.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

Hansa names Maria Tornsen to lead US business
Biotechnology
Hansa names Maria Tornsen to lead US business
13 May 2025
Pharmaceutical
Wegovy offers early protection against heart disease—even before significant weight loss
13 May 2025
Generics
India prioritizes generic pharma sector in UK trade talks, declines data exclusivity
13 May 2025
Pharmaceutical
Recipharm and PLG team up to streamline development and approvals
13 May 2025
Pharmaceutical
$700+ million US investment by Genentech and Roche
13 May 2025
Pharmaceutical
Changing Bayer beats earnings estimate; shares rocket
13 May 2025
Pharmaceutical
Trump targets foreign "freeloaders" with new pricing order
13 May 2025

Company Spotlight

Boundless Bio is a biotechnology company seeking to develop novel therapies to treat cancer.






The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze